Yep I agree swe77...the PAR deal is most likely a paltry 2.5% and we only had the stellar Q2 due to the 180 day exclusivity period on the 4 additional strengths.
It's clearly gonna take MNK a while to ramp up SeroquelXR sales to their target levels too...so for now I'm just gonna forget about this stock until year end earnings come out sometime towards the end of February 2018.
Maybe something positive begins to occur next year...but ever since the FocalinXR approval of 4 years ago there's been nothing but endless disappointments here and the market is speaking loudly about what they think of Odidi's ability to unlock any value here.
Market Data 
Markets 
AI
